Clinical Trials Arena September 19, 2025
In MRD-evaluable patients, 100% achieved MRD negativity after six cycles of treatment.
Johnson & Johnson’s (J&J’s) multiple myeloma combination of Tecvayli (teclistamab-cqyv) and Darzalex Faspro (daratumumab and hyaluronidase-fihj) as an induction treatment has elicited a 100% overall response (OR) in transplant-eligible, newly diagnosed patients.
Updated results from the Phase II MajesTEC-5 trial (NCT05695508) show that 100% of patients achieved OR after treatment with the combination therapy. Of the 46 minimal residual disease (MRD)-evaluable patients, 100% achieved MRD negativity by next-generation flow at 10-5 sensitivity threshold after cycle six.
Overall, 85.7% of patients achieved a complete response or better (≥CR) and were MRD-negative at cycle six, and 96% of patients successfully completed stem cell mobilisation with a median total stem cell...
Today's Sponsors
Today's Sponsor